Jasper Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announces its participation in three upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference (Nov 18-19) with a fireside chat on Nov 18 at 9:45 AM ET, the Jefferies London Healthcare Conference (Nov 19-21), and the 7th Annual Evercore ISI HealthCONx Conference (Dec 3-5) with a fireside chat on Dec 3 at 3:25 PM ET. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences:

Stifel 2024 Healthcare Conference
Conference Dates: November 18 – 19, 2024
Presentation Date: Monday, November 18, 2024, 9:45 a.m. ET
Presentation Format: Fireside Chat

Jefferies London Healthcare Conference 2024
Conference Dates: November 19-21, 2024

7^th Annual Evercore ISI HealthCONx Conference
Conference Dates: December 3-5, 2024
Presentation Date: Tuesday, December 3, 2024, 3:25 p.m. ET
Presentation Format: Fireside Chat

Live webcasts of the presentations will be available on the Events & News – Events page of Jasper's Investor Relations website. An archived replay of each presentation will be available on Jasper's website for 30 days following the applicable live broadcast.

About Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and asthma and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 160 dosed participants and healthy volunteers, with clinical outcomes in CIndU and as a conditioning agent in SCID, acute myeloid leukemia, myelodysplastic syndromes, FA, and SCD. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Jasper’s presentations at the Stifel 2024 Healthcare Conference, the Jefferies 2024 London Healthcare Conference 2024 and the 7th Annual Evercore ISI HealthCONx Conference, and briquilimab’s potential to address mast cell driven diseases such as CSU, CIndU and asthma. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com

Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
agray@jaspertherapeutics.com

Lauren Walker (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com

FAQ

What investor conferences will Jasper Therapeutics (JSPR) attend in November-December 2024?

Jasper Therapeutics will attend three conferences: Stifel Healthcare Conference (Nov 18-19), Jefferies London Healthcare Conference (Nov 19-21), and Evercore ISI HealthCONx Conference (Dec 3-5).

What is briquilimab being developed for by Jasper Therapeutics (JSPR)?

Briquilimab is being developed as a novel antibody therapy targeting c-Kit (CD117) to treat mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

When will Jasper Therapeutics (JSPR) present at the Stifel 2024 Healthcare Conference?

Jasper Therapeutics will present a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 9:45 AM ET.

How long will the webcasts of Jasper Therapeutics (JSPR) presentations be available?

The archived replays of each presentation will be available on Jasper's website for 30 days following the live broadcast.